Advertisement
Articles
Advertisement

Focus on Alliances 11/3/06

Fri, 11/03/2006 - 11:40am
COLLABORATIONS

MD Biosciences and Medisyn to Team Up
MD Biosciences, Zürich, Switzerland, and Medisyn Technologies, Minnetonka, Minn., announced a collaboration to develop small molecules targeting inflammatory and neurological diseases. The collaboration aims to develop pre-clinically validated lead compounds within joint and airway inflammations as well as Multiple Sclerosis, pain relief and Parkinson's disease.
Full Article

Metabasis Forms Research Alliance with Idenix
Metabasis Therapeutics Inc., la Jolla, Calif., focused on the discovery, development, and commercialization of novel drugs to address chronic diseases, announced a two-year research collaboration agreement with Idenix Pharmaceuticals Inc., Cambridge, Mass., to develop second-generation nucleoside analog drug candidates to treat the hepatitis C virus.
Full Article

Roche and InterMune Form Alliance on HCV Protease Inhibitors
Roche, Basel, Switzerland, and InterMune Inc., Brisbane, Calif., entered into an exclusive worldwide collaboration agreement to develop and commercialize products from InterMune's hepatitis C virus (HCV) protease inhibitor program.
Full Article

U.S. Genomics and Lahey Clinic to Study MicroRNAs
U.S. Genomics Inc., Woburn, Mass., and Lahey Clinic, Burlington, Mass., signed a discovery agreement to study the role microRNAs play in the development of urologic cancers in order to develop more accurate prognoses for bladder and prostate cancer patients.
Full Article

Organon and BrainCells to Collaborate on CNS Drugs
Organon, Roseland, N.J., and Oss, The Netherlands, the human health care business unit of Akzo Nobel, and BrainCells Inc., San Diego, Calif., will collaborate in the discovery and development of drugs to treat central nervous system (CNS) disorders.
Full Article

Cambridge Antibody and MSM Enter Drug Discovery Collaboration
Cambridge Antibody Technology, Cambridge, UK, and MSM Protein Technologies, East Kingston, N.H., have formed a two-year drug discovery collaboration aimed at developing antibody-based drugs targeting multi-spanning membrane proteins.
Full Article

Arbor Vita and NoNO to Collaborate on Stroke Treatment
Arbor Vita Corp., Sunnyvale, Calif., and NoNO Inc., Toronto, Canada, a Canadian biotechnology company focused on neurological diseases, announced their partnership to develop and commercialize drugs to treat stroke. The collaboration combines Arbor Vita's PDZ-based Drug Discovery Platform with NoNO's expertise in neurological disorders.
Full Article

Sanofi Pasteur and Pediatric Dengue Vaccine Initiative Partner
Sanofi pasteur, Lyon, France, the vaccines business of sanofi-aventis, and the Pediatric Dengue Vaccine Initiative, New York, announced a partnership to develop and make a Dengue vaccine widely available for the global prevention of Dengue fever, the second most widespread tropical disease after malaria.
Full Article

GTC Biotherapeutics and LFB Biotechnologies Enter Collaboration
GTC Biotherapeutics Inc., Framingham, Mass., and LFB Biotechnologies, Paris, entered into a strategic collaboration to develop selected recombinant plasma proteins and monoclonal antibodies using GTC’s transgenic production platform.
Full Article

UCB and Biogen Idec to Join Forces for Oral MS Drug
UCB, Brussels, Belgium and Biogen Idec, Cambridge, Mass., announced a global collaboration to jointly develop and commercialize CDP323 to treat relapsing-remitting multiple sclerosis (MS) and other potential indications. CDP323 is an orally active small molecule alpha4-integrin inhibitor expected to enter phase II clinical trials next year.
Full Article

ACQUISITIONS

Merck to Acquire Sirna Therapeutics
Merck & Co. Inc., Whitehouse Station, NJ entered into a definitive agreement to acquire Sirna Therapeutics Inc., San Francisco, a leader in developing a new class of medicines based on RNA interference (RNAi) technology.
Full Article

Forbes Medi-Tech Acquires TheraPei
Forbes Medi-Tech Inc., Vancouver, Canada, has acquired TheraPei Pharmaceuticals Inc., San Diego, Calif., a privately held company focused on developing novel pharmaceuticals directed at diabetes and metabolic diseases.
Full Article

Pfizer to Acquire PowderMed
Pfizer Inc., New York, entered into an agreement to acquire PowderMed Ltd., Oxford, UK, a privately held company specializing in DNA-based vaccines. PowderMed developed a proprietary technology to deliver DNA directly to the cells of the body's immune system.
Full Article

Lilly to Acquire ICOS
Eli Lilly and Co., Indianapolis, Ind., signed a definitive agreement to acquire ICOS Corp., Bothell, Wash., in a cash transaction. Since 1998, Lilly and ICOS have been partners in Lilly ICOS LLC, the joint venture that manufactures, markets and sells Cialis (tadalafil).
Full Article

MERGERS

Dauphin Technology Merges with GeoVax
Dauphin Technology, Inc., Schaumburg, Ill., completed its merger with GeoVax Inc., Atlanta. The combined companies will operate as GeoVax Labs Inc.
Full Article

TorreyPines Completes Merger with Axonyx
TorreyPines Therapeutics Inc., la Jolla, Calif., completed a merger with Axonyx Inc. The merger creates a publicly traded biopharmaceutical company that discovers and develops treatments for diseases and disorders of the central nervous system.
Full Article


Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading